Brainstorm Cell Therapeutics Price to Book Ratio

As of the most recent data, BCLI shows a P/B ratio of -0.4. That is above the Healthcare sector average of -49.54. Scroll down for historical charts and peer comparison views.

The Healthcare sector average P/B ratio is about -49.54. Brainstorm Cell Therapeutics is at -0.4, which is higher that average. That is roughly 99.2% above the sector mean. Use the comparison chart on this page to see how BCLI stacks up against individual peers as well.

Investors watch BCLI's P/B ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Brainstorm Cell Therapeutics's latest reading is -0.4. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this price-to-book ratio page, Stockcircle has Brainstorm Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/B ratio (currently -0.4) with ownership activity and broader fundamentals.

The Healthcare average P/B ratio is about -49.54, while BCLI is at -0.4. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.